P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 35 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016', provides in depth analysis on P27 (Negative Regulatory Factor or Nef) targeted pipeline therapeutics. 

The report provides comprehensive information on the P27 (Negative Regulatory Factor or Nef) , targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in P27 (Negative Regulatory Factor or Nef) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for P27 (Negative Regulatory Factor or Nef) 
- The report reviews P27 (Negative Regulatory Factor or Nef) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in P27 (Negative Regulatory Factor or Nef) targeted therapeutics and enlists all their major and minor projects 
- The report assesses P27 (Negative Regulatory Factor or Nef) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to P27 (Negative Regulatory Factor or Nef) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for P27 (Negative Regulatory Factor or Nef) 
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding P27 (Negative Regulatory Factor or Nef) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

 Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
P27 (Negative Regulatory Factor or Nef) Overview 6
Therapeutics Development 7
P27 (Negative Regulatory Factor or Nef) - Products under Development by Stage of Development 7
P27 (Negative Regulatory Factor or Nef) - Products under Development by Therapy Area 8
P27 (Negative Regulatory Factor or Nef) - Products under Development by Indication 9
P27 (Negative Regulatory Factor or Nef) - Pipeline Products Glance 10
Late Stage Products 10
Early Stage Products 11
P27 (Negative Regulatory Factor or Nef) - Products under Development by Companies 12
P27 (Negative Regulatory Factor or Nef) - Products under Development by Universities/Institutes 14
P27 (Negative Regulatory Factor or Nef) - Therapeutics Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
P27 (Negative Regulatory Factor or Nef) - Drug Profiles 22
HIV vaccine - Drug Profile 22
Product Description 22
Mechanism Of Action 22
R&D Progress 22
HIV vaccine - Drug Profile 23
Product Description 23
Mechanism Of Action 23
R&D Progress 23
HIV vaccine 1 - Drug Profile 24
Product Description 24
Mechanism Of Action 24
R&D Progress 24
HIV-1 vaccine 1 - Drug Profile 25
Product Description 25
Mechanism Of Action 25
R&D Progress 25
HIV-1 vaccine 5 - Drug Profile 26
Product Description 26
Mechanism Of Action 26
R&D Progress 26
Monoclonal Antibody Conjugate to Inhibit Gag, Nef, Pol for HIV - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
MVATG-17401 - Drug Profile 28
Product Description 28
Mechanism Of Action 28
R&D Progress 28
Small Molecules to Inhibit Nef for HIV-1 Infections - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Tatbeclin-1 - Drug Profile 30
Product Description 30
Mechanism Of Action 30
R&D Progress 30
P27 (Negative Regulatory Factor or Nef) - Dormant Projects 31
P27 (Negative Regulatory Factor or Nef) - Featured News & Press Releases 33
Jan 02, 2015: HIV vaccines should avoid viral target cells, primate model study suggests 33
Appendix 34
Methodology 34
Coverage 34
Secondary Research 34
Primary Research 34
Expert Panel Validation 34
Contact Us 34
Disclaimer 35

List of Tables

Number of Products under Development for, H2 2016 7
Number of Products under Development by Therapy Area, H2 2016 8
Number of Products under Development by Indication, H2 2016 9
Comparative Analysis by Late Stage Development, H2 2016 10
Comparative Analysis by Early Stage Products, H2 2016 11
Number of Products under Development by Companies, H2 2016 12
Products under Development by Companies, H2 2016 13
Number of Products under Investigation by Universities/Institutes, H2 2016 14
Products under Investigation by Universities/Institutes, H2 2016 15
Assessment by Monotherapy/Combination Products, H2 2016 16
Number of Products by Stage and Mechanism of Action, H2 2016 17
Number of Products by Stage and Route of Administration, H2 2016 19
Number of Products by Stage and Molecule Type, H2 2016 21
Dormant Projects, H2 2016 31
Dormant Projects (Contd..1), H2 2016 32